News Releases

October 31, 2019
Research & Development: MP0310 (FAP x 4-1BB): First patient dosed in phase 1 trial for this tumor-localized immune-modulator, representing a key milestone as the first novel therapeutic design of an immuno-oncology DARPin® candidate in clincial development (in co-development with Amgen) MP0250
Displaying 81 - 90 of 151
* These releases may contain price sensitive information